Detalles de la búsqueda
1.
Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder: Results of 2 Phase 3, Randomized, Double-blind, Multicenter, Placebo-Controlled Trials.
J Clin Psychopharmacol
; 42(5): 429-439, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35652746
2.
Screening for Adult ADHD.
Curr Psychiatry Rep
; 22(12): 72, 2020 10 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-33095375
3.
Establishing US norms for the Adult ADHD Self-Report Scale (ASRS-v1.1) and characterising symptom burden among adults with self-reported ADHD.
Int J Clin Pract
; 73(1): e13260, 2019 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-30239073
4.
Test-retest reliability of the adult ADHD Self-Report Scale (ASRS) v1.1 Screener in non-ADHD controls from a primary care physician practice.
Fam Pract
; 35(3): 336-341, 2018 05 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-29177453
5.
Executive function in adults with attention-deficit/hyperactivity disorder during treatment with atomoxetine in a randomized, placebo-controlled, withdrawal study.
J Clin Psychopharmacol
; 34(4): 461-6, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24977716
6.
Measuring Quality Care for Adult ADHD Patients: How Much Does Gender and Gender Identity Matter?
J Atten Disord
; 28(3): 364-376, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38156652
7.
The Role of Age in Adult ADHD Quality Care: A Longitudinal Analysis of Electronic Health Record Data.
J Atten Disord
; 28(5): 913-922, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38156704
8.
A Single-Blind, Placebo Controlled Trial of Triple Beaded Mixed Amphetamine Salts in DSM-5 Adults With ADHD Assessing Effects Throughout the Day.
J Atten Disord
; 28(5): 810-819, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38214178
9.
Differences in Primary Care Management of Patients With Adult Attention Deficit Hyperactivity Disorder (ADHD) Based on Race and Ethnicity.
J Atten Disord
; 28(5): 923-935, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38214134
10.
Pilot Study of Prism EFP NeuroFeedback in Adult ADHD.
J Atten Disord
; 28(5): 905-912, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38152997
11.
Neurobiological basis of reinforcement-based decision making in adults with ADHD treated with lisdexamfetamine dimesylate: Preliminary findings and implications for mechanisms influencing clinical improvement.
J Psychiatr Res
; 170: 19-26, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38101205
12.
Amygdala-derived-EEG-fMRI-pattern neurofeedback for the treatment of chronic post-traumatic stress disorder. A prospective, multicenter, multinational study evaluating clinical efficacy.
Psychiatry Res
; 333: 115711, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38325159
13.
Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial.
J Clin Psychopharmacol
; 33(1): 45-54, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23277268
14.
Self-Reported quality of life in adults with attention-deficit/hyperactivity disorder and executive function impairment treated with lisdexamfetamine dimesylate: a randomized, double-blind, multicenter, placebo-controlled, parallel-group study.
BMC Psychiatry
; 13: 253, 2013 Oct 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-24106804
15.
Progress and Pitfalls in the Provision of Quality Care for Adults With Attention Deficit Hyperactivity Disorder in Primary Care.
J Atten Disord
; 27(6): 575-582, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36803110
16.
Updates in Pharmacologic Strategies in Adult Attention-Deficit/Hyperactivity Disorder.
Child Adolesc Psychiatr Clin N Am
; 31(3): 553-568, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35697401
17.
Economic burden of attention-deficit/hyperactivity disorder among children and adolescents in the United States: a societal perspective.
J Med Econ
; 25(1): 193-205, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35068300
18.
Economic burden of attention-deficit/hyperactivity disorder among adults in the United States: a societal perspective.
J Manag Care Spec Pharm
; 28(2): 168-179, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-34806909
19.
Long-term safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: an open-label, dose-titration, 1-year study.
J Clin Psychopharmacol
; 31(1): 108-14, 2011 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-21192153
20.
Divergence by ADHD subtype in smoking cessation response to OROS-methylphenidate.
Nicotine Tob Res
; 13(10): 1003-8, 2011 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-21652734